SHINE Medical Technologies

27 articles about SHINE Medical Technologies

• SHINE Technologies, LLC Announces Submission of FDA Drug Master File for Non-Carrier-Added Lutetium-177

  4/8/2024

  SHINE Technologies, LLC, a pioneer in next-generation fusion-based technology, becomes North America's largest producer of non-carrier added lutetium-177 chloride, a cutting-edge radiopharmaceutical used in precision cancer treatment, with a Drug Master File to the U.S. Food and Drug Administration.

• SHINE Technologies and Nucleus RadioPharma Partner to Advance Radioligand Cancer Treatments

  11/16/2023

  SHINE Technologies today announced a long-term supply agreement with Nucleus RadioPharma, the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals.

• Shine Technologies and Curadh MTR Announce Expanded Strategic Partnership to Advance Cancer Therapies using Terbium and Lutetium

  9/11/2023

  The strategic collaboration between Curadh MTR Inc. and SHINE Technologies marks a pivotal moment in the advancement of cancer therapies.

• SHINE Technologies Appoints Experienced Company Builder to Board of Directors

  6/7/2023

  SHINE Technologies, LLC, a next-generation fusion technology company, announced the appointment of Dr. Frederick Robertson to the company's board of directors.

• SHINE Gets Dutch Approval for Project to Improve Patient Access to Promising New Nuclear Medicine

  10/17/2022

  SHINE Technologies, a next-generation fusion technology company, and SHINE Europe announced today that the Dutch government has approved a substantial grant proposal to develop a plan to produce a variety of terbium isotopes for use in nuclear medicine.

• Phoenix Names Tom D'Orazio CEO

  8/16/2022

  SHINE Technologies, LLC, a next-generation fusion technology company, announced Tom D'Orazio has joined as the CEO of Phoenix LLC.

• SHINE Technologies Submits Drug Master File with the U.S. Food and Drug Administration for Non-Carrier-Added Lutetium-177 Chloride

  7/29/2022

  SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, today announced the company has submitted a Drug Master File (DMF) with the U.S. Food and Drug Administration for non-carrier-added lutetium-177 (Lu-177) chloride, a radiopharmaceutical at the forefront of precision cancer treatment.

• SHINE Announces Chris Vessell as General Manager of Therapeutics Division

  5/23/2022

  SHINE Technologies, LLC, a next-generation nuclear technology company, announced Chris Vessell has joined as General Manager of the Therapeutics Division.

• Telix and SHINE partner for Lutetium-177 Supply

  2/10/2022

  Telix Pharmaceuticals Limited announces a new global clinical supply agreement with Wisconsin-based SHINE Technologies, LLC for highly pure no-carrier-added lutetium-177, a therapeutic isotope used in Telix’s portfolio of molecularly targeted radiation investigational products.

• SHINE’s new name highlights technology competencies and multiple phase opportunities

  9/22/2021

  SHINE Medical Technologies LLC announced that the company has changed its name to SHINE Technologies LLC.

• SHINE Medical announces that its isotope production facility is weathertight

  3/25/2021

  SHINE Medical Technologies LLC today announced that construction of the exterior structure of its first-of-a-kind medical isotope production facility is complete and the building is weathertight, a major milestone with significance for SHINE, the medical isotope industry and patients around the world.

• SHINE Medical Breaks Ground for 54,000-Square-Foot Headquarters and Therapeutics Production Facility

  12/16/2020

  SHINE Medical Technologies LLC announced that the company has broken ground on a new 54,000-square-foot facility that will house its corporate headquarters and a large-scale production facility for the Therapeutics division it established last year.

• Von Gahlen Building Major Component of SHINE’s One-of-a-Kind Isotope Plant

  11/23/2020

  SHINE Medical Technologies LLC and Von Gahlen International Inc. announced that Von Gahlen will build and install the “supercell,” a bank of 10 hot cells, for SHINE’s U.S. medical isotope production facility in Janesville, Wis.

• SHINE Announces First Sales of Its Non-carrier-added Lutetium-177

  11/4/2020

  SHINE Medical Technologies LLC announced that its Therapeutics division has made its first commercial sales of lutetium-177 to multiple customers.

• SHINE Closes $80-million Series C Financing Supported by Fidelity Management and Research Company LLC

  9/2/2020

  SHINE Medical Technologies LLC, a nuclear technology company focused on becoming the world’s leading producer of medical isotopes, announced that it has closed an $80-million Series C financing.

• SHINE and IOCB Prague deliver patient dose quantities of lutetium-177 to GE Healthcare, advance therapeutic isotope toward commercialization

  1/21/2020

  SHINE Medical Technologies LLC, the Institute of Organic Chemistry and Biochemistry (IOCB Prague) and GE Healthcare today announced the production of patient dose quantities of the therapeutic isotope lutetium-177 (Lu-177).

• Nuclear Regulatory Commission Accepts SHINE’s Operating License Application, Technical Review Schedule to be Finalized This Fall

  10/15/2019

  SHINE Medical Technologies LLC announced that the U.S. Nuclear Regulatory Commission has accepted SHINE’s Operating License Application to operate its medical isotope production facility in Janesville, Wis.

• SHINE closes $50-million financing with Oaktree to support execution of construction and commercialization plans

  10/7/2019

  The financing supports the ongoing construction of SHINE’s medical isotope production facility and its commercialization of diagnostic and therapeutic isotopes, including molybdenum-99 (Mo-99) and lutetium-177

• Nuclear medicine industry expert Buurlage joins SHINE

  9/4/2019

  SHINE Medical Technologies LLC today announced the appointment of Harrie Buurlage as vice president, European operations.

• Former House Speaker Paul Ryan appointed to SHINE’s Board of Directors

  8/26/2019

  SHINE Medical Technologies, LLC today announced the appointment of Paul D. Ryan to the company’s board of directors.